Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124134 | 0.90 | TRPA1 (0.32) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL6127878 | 0.84 | GPR55 (0.32) | GPR55TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL6127812 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL25636165 | 0.72 | MRGPRX1 (0.36) | LMNA | |
| SCHEMBL6124249 | 0.71 | PSEN1 (0.40) | — | |
| SCHEMBL24498588 | 0.71 | GABRA1 (0.39) | LMNASLC6A2HTR2B | |
| SCHEMBL29340892 | 0.71 | KDM4E (0.31) | GPR55TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL12616889 | 0.70 | GPR35 (0.34) | — | |
| SCHEMBL8737563 | 0.68 | GPR55 (0.39) | GPR55TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL24090598 | 0.67 | CYP1A2 (0.39) | LMNASLC6A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | GPR55 1767/4885TRPA1 4712/4885LMNA 2080/4885 |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | GPR55 1250/4885TRPA1 4194/4885LMNA 1910/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | GPR55 1389/4885TRPA1 4440/4885LMNA 1740/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | GPR55 1220/4885TRPA1 4391/4885LMNA 652/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | GPR55 1495/4885TRPA1 4671/4885LMNA 1968/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | GPR55 1488/4885TRPA1 4305/4885LMNA 676/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | GPR55 1244/4885TRPA1 4716/4885LMNA 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.